Gastric Cancer 98 Gene Testing applies a targeted next-generation sequencing panel to tumor-derived nucleic acids, turning the molecular makeup of gastric adenocarcinoma into a concrete list of actionable findings. Instead of a single marker, the assay surveys 98 genes implicated in gastric carcinogenesis, giving oncology teams a broader evidence base for therapy selection. For hospitals, reference labs, and distributors, the payoff is a standardized workflow with reproducible reports and predictable turnaround.
The panel interrogates both DNA and RNA from a single preserved sample. On the DNA side, it captures single-nucleotide variants, small indels, copy-number alterations, and microsatellite status across the curated gene set. On the RNA side, it detects gene fusions and measures expression shifts that protein-coding changes alone would miss. Hybrid-capture preparation yields millions of reads aligned to a reference genome and filtered for tumor-specific signals. A bioinformatics pipeline then classifies each alteration by clinical relevance, separating drivers from passengers so the physician receives a prioritized interpretation rather than a raw variant dump.
The test is indicated for newly diagnosed and refractory gastric adenocarcinoma where biomarker-driven therapy is under consideration. It supports identification of HER2 amplification, Claudin 18.2 status, MET amplification, FGFR2 rearrangements, and homologous-repair defects that inform PARP or platinum strategies. It is also applicable to tumors with ambiguous histology, where molecular subtyping resolves lineage and refines the differential. Because the panel spans DNA and RNA, it remains informative even when tumor content is modest, provided the starting material meets quality thresholds.
No pharmacological administration is involved; the assay is performed on submitted biospecimens. A formalin-fixed paraffin-embedded block or 5–10 unstained slides accompanied by a pathology report are typical inputs. Laboratories recommend a minimum tumor content of 20% and DNA yield above 50 ng for reliable calls. Results are delivered as a written report with an interactive variant summary, usually within 7–10 working days of sample receipt, and a molecular tumor board can be arranged for complex cases.
Source specimens at 2–8°C and ship with cold-chain packaging to preserve nucleic-acid integrity; avoid repeated freeze–thaw cycles that fragment DNA. For distributors, lot traceability and standardized reagent sourcing protect consistency across sites. Minimum order quantity and lead time should be confirmed against regional import rules, and a documented chain of custody is essential when samples cross borders for centralized sequencing.
Q: Which patients benefit most from the 98-gene panel? A: Patients with advanced or treatment-resistant gastric adenocarcinoma gain the most, because the broader gene set surfaces rare but targetable alterations that single-marker tests overlook.
Q: How does the combined DNA-and-RNA design improve accuracy? A: Scanning both strands catches fusions and expression changes invisible to DNA-only panels, reducing false negatives in tumors with a low mutation burden.
Q: What sample quality is required for a valid report? A: A pathology-reviewed FFPE block or unstained slides with at least 20% tumor content and 50 ng of DNA typically yield reportable results.
Q: How are the results used in therapy selection? A: The report maps each alteration to approved or trial-based options, letting the oncology team match a patient to targeted or immune therapy without reordering multiple single tests.
Gastric Cancer 98 Gene Testing applies a targeted next-generation sequencing panel to tumor-derived nucleic acids, turning the molecular makeup of gastric adenocarcinoma into a concrete list of actionable findings. Instead of a single marker, the assay surveys 98 genes implicated in gastric carcinogenesis, giving oncology teams a broader evidence base for therapy selection. For hospitals, reference labs, and distributors, the payoff is a standardized workflow with reproducible reports and predictable turnaround.
The panel interrogates both DNA and RNA from a single preserved sample. On the DNA side, it captures single-nucleotide variants, small indels, copy-number alterations, and microsatellite status across the curated gene set. On the RNA side, it detects gene fusions and measures expression shifts that protein-coding changes alone would miss. Hybrid-capture preparation yields millions of reads aligned to a reference genome and filtered for tumor-specific signals. A bioinformatics pipeline then classifies each alteration by clinical relevance, separating drivers from passengers so the physician receives a prioritized interpretation rather than a raw variant dump.
The test is indicated for newly diagnosed and refractory gastric adenocarcinoma where biomarker-driven therapy is under consideration. It supports identification of HER2 amplification, Claudin 18.2 status, MET amplification, FGFR2 rearrangements, and homologous-repair defects that inform PARP or platinum strategies. It is also applicable to tumors with ambiguous histology, where molecular subtyping resolves lineage and refines the differential. Because the panel spans DNA and RNA, it remains informative even when tumor content is modest, provided the starting material meets quality thresholds.
No pharmacological administration is involved; the assay is performed on submitted biospecimens. A formalin-fixed paraffin-embedded block or 5–10 unstained slides accompanied by a pathology report are typical inputs. Laboratories recommend a minimum tumor content of 20% and DNA yield above 50 ng for reliable calls. Results are delivered as a written report with an interactive variant summary, usually within 7–10 working days of sample receipt, and a molecular tumor board can be arranged for complex cases.
Source specimens at 2–8°C and ship with cold-chain packaging to preserve nucleic-acid integrity; avoid repeated freeze–thaw cycles that fragment DNA. For distributors, lot traceability and standardized reagent sourcing protect consistency across sites. Minimum order quantity and lead time should be confirmed against regional import rules, and a documented chain of custody is essential when samples cross borders for centralized sequencing.
Q: Which patients benefit most from the 98-gene panel? A: Patients with advanced or treatment-resistant gastric adenocarcinoma gain the most, because the broader gene set surfaces rare but targetable alterations that single-marker tests overlook.
Q: How does the combined DNA-and-RNA design improve accuracy? A: Scanning both strands catches fusions and expression changes invisible to DNA-only panels, reducing false negatives in tumors with a low mutation burden.
Q: What sample quality is required for a valid report? A: A pathology-reviewed FFPE block or unstained slides with at least 20% tumor content and 50 ng of DNA typically yield reportable results.
Q: How are the results used in therapy selection? A: The report maps each alteration to approved or trial-based options, letting the oncology team match a patient to targeted or immune therapy without reordering multiple single tests.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
